Saredutant

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Saredutant
Saredutant.svg
Systematic (IUPAC) name
N-[(2S)-4-(4-acetamido-4-phenylpiperidin-1-yl)- 2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide
Clinical data
Legal status
?
Identifiers
CAS number 142001-63-6
ATC code None
PubChem CID 104974
IUPHAR ligand 2111
ChemSpider 94726 YesY
ChEMBL CHEMBL308148 YesY
Chemical data
Formula C31H35Cl2N3O2 
Mol. mass 552.5345 g/mol
 YesY (what is this?)  (verify)

Saredutant (SR-48,968) is a drug that acts as a NK2 receptor antagonist. It was under development by Sanofi-Aventis as a novel antidepressant and anxiolytic and made it to phase III clinical trials. However, in May 2009, Sanofi-Aventis published its quarterly results and announced the cessation of 14 research/development projects, among which was saredutant for the treatment of major depressive disorder.[1]

See also[edit]

References[edit]

  1. ^ http://www.sanofi-aventis.com/binaries/Lettre18_FR_Web_acc_tcm29-25341.pdf Letter to the stockholders of Sanofi-Aventis on May 2009